-
Lyophilized workshop -
Marketing Center Building -
Lyophilized workshop -
API plant
INTEGRITY FIRST
KPC Pharmaceuticals, Inc (hereinafter be abbreviated as ‘KPC’, 600422 SH) was established in March 1951 and floated on the Shanghai Stock Exchange in December 2000. With its considerable professional experience in pharmaceutical industry, the company is listed as one of the new key national high-tech companies and one of the Top 100 companies in the Chinese medical industry. The company’s brands such as Luotai®, Tianxuanqing®, Artemedine®, Artem® and Arco® currently enjoy a good reputation both at home and abroad.
KPC is a pharmaceutical company which focused on innovative natural botanical drugs and integrates R&D, production, marketing, commercial wholesales and international marketing. Its business scope covers traditional Chinese medicine, chemical medicine and medicinal circulation. Companies owned by KPC include the Kunming Traditional Chinese Medicine Co. Ltd., Kingtide Notoginseng Industry Co. Ltd., Xishuangbanna Pharmaceutical Co. Ltd., Kunming Pharmaceutical Commercial Co. Ltd., Kunming Baker Norton Pharmaceutical Co. Ltd., Nukus Botanic Technology Co. Ltd., Kunming Yinnuo Medical Technology Co. Ltd., and Beijing Holley-Cotec Pharmaceuticals Co. Ltd. KPC also boasts a large-scale manufacturing center, Xuesaitong drug research institute and postdoctoral workstation. Situated in the National Biological Industry Base of the Kunming High-tech Zone, the "KPC Bio-Pharmaceutical Science and Technology Park" will be a large-scale, professional and international biomedical park, taking the lead both at home and abroad.
Based on Yunnan’s abundant plant resources, KPC has developed more than 40 new natural botanical drugs, including the artemether series, panax notoginseng series, gastrodine series, special Chinese medicines and special ethnic drugs. With multiple national patents, KPC has filled several gaps in the pharmaceutical industry both at home and abroad. Being highly renowned and popular in terms of treatments for cardio-cerebral-vascular diseases, nervous system diseases and malaria, KPC has made positive and significant contributions to the health of human.
KPC's unique core competitive advantages include its outstanding R&D ability, abundant product resources, strong integrated manufacturing system, internationally compatible quality management system and its international marketing team. In the future, following the principle "From nature; For Human Health", KPC will develop into an international pharmaceutical supplier focusing on cardio-cerebral-vascular disease and chronic disease treatment. At the same time, it will continue striving to be an outstanding and globally famous brand in terms of cardio-cerebral-vascular drugs.
